Literature DB >> 28085142

Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement.

T Y Chen1, M G Keeney2, A V Chintakuntlawar3, D L Knutson4, S Kloft-Nelson4, P T Greipp2, J A Garrity5, D R Salomao2, J J Garcia2.   

Abstract

PurposeAdenoid cystic carcinoma (ACC) represents ~10-15% of salivary neoplasms and almost universally exhibits a lethal clinical course. ACC is also known to occur in the lacrimal gland. ACC is characterized by its heterogeneous morphology and may demonstrate tubular, cribriform, and/or solid architectural patterns. Unfortunately, these histopathological features are not specific to ACC and can be seen in other salivary gland-type neoplasms, introducing a diagnostic dilemma. The discovery of fusion transcripts has revolutionized the diagnosis, surveillance, and treatment of epithelial malignancies. In several anatomic subsites ACC is frequently characterized by a fusion transcript involving genes MYB and NFIB; more specifically, t(6;9)(q22-23;p23-24). This study explores the incidence of MYB rearrangement in cases of lacrimal gland ACC using fluorescent in situ hybridization.Materials and methodsRetrospective clinical and histopathological review of 12 cases of lacrimal gland ACC seen at Mayo Clinic over a 25-year period (1990-2015) was performed. Demographic and clinical data were obtained from medical records. Surgical pathology archival material including H&E slides and immunostains was re-examined. Formalin-fixed paraffin-embedded material was further evaluated using immunohistochemistry when appropriate. Fluorescent in situ hybridization (FISH) using a MYB break-apart probe was applied to all histologically confirmed cases of ACC and benign salivary gland parenchyma.ResultsThe median patient age was 53.6 years (range 12-64) and distributed equally by gender (six male and six female). Rearrangement of MYB was identified using FISH in seven cases (58%). Twenty-five sections of benign salivary gland parenchyma showed no evidence of MYB rearrangement. Primary surgical resection was most common treatment, and 78% of the patient received adjuvant radiation therapy. Median overall survival (OS) was 11 years. Rearrangement of MYB did not affect OS.ConclusionsIn summary, our results indicate that the MYB rearrangement defines a significant subset of lacrimal gland ACCs. Importantly, FISH for MYB rearrangement may be used as a diagnostic tool during pathological examination of lacrimal gland neoplasms. Our results showed no relationship between rearrangement status and clinical outcome. Lastly, the presence of t(6;9) in ACC may provide a platform for molecular-targeting strategies in the future.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28085142      PMCID: PMC5437320          DOI: 10.1038/eye.2016.307

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  22 in total

1.  Bone invasion by adenoid cystic carcinoma of the lacrimal gland: preoperative imaging assessment and surgical considerations.

Authors:  Michelle D Williams; Nagham Al-Zubidi; J Matthew Debnam; Roman Shinder; Franco DeMonte; Bita Esmaeli
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2010 Nov-Dec       Impact factor: 1.746

2.  Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases.

Authors:  R L Font; S L Smith; R G Bryan
Journal:  Arch Ophthalmol       Date:  1998-05

3.  Epithelial lacrimal gland tumors: pathologic classification and current understanding.

Authors:  Ezekiel Weis; Jack Rootman; Thomas J Joly; Kenneth W Berean; Hind M Al-Katan; Sylvia Pasternak; Giulio Bonavolontà; Diego Strianese; Peerooz Saeed; Kenneth A Feldman; Sumalee Vangveeravong; Jocelyne S Lapointe; Valerie A White
Journal:  Arch Ophthalmol       Date:  2009-08

4.  Epithelial lacrimal gland tumors: a clinicopathological study of 18 cases.

Authors:  Danyel E C Perez; Fábio R Pires; Oslei P Almeida; Luiz P Kowalski
Journal:  Otolaryngol Head Neck Surg       Date:  2006-02       Impact factor: 3.497

5.  Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome.

Authors:  Yoshitsugu Mitani; Pulivarthi H Rao; P Andrew Futreal; Dianna B Roberts; Philip J Stephens; Yi-Jue Zhao; Li Zhang; Mutsumi Mitani; Randal S Weber; Scott M Lippman; Carlos Caulin; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

6.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.

Authors:  Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

7.  Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma.

Authors:  Anja C Roden; Patricia T Greipp; Darlene L Knutson; Sara M Kloft-Nelson; Sarah M Jenkins; Randolph S Marks; Marie Christine Aubry; Joaquín J García
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

Review 8.  Epithelial tumors of the lacrimal gland: an update.

Authors:  Francesco P Bernardini; Martìn H Devoto; J Oscar Croxatto
Journal:  Curr Opin Ophthalmol       Date:  2008-09       Impact factor: 3.761

9.  Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Authors:  Daniel Wetterskog; Maria Angeles Lopez-Garcia; Maryou B Lambros; Roger A'Hern; Felipe C Geyer; Fernanda Milanezi; Maria C Cabral; Rachael Natrajan; Arnaud Gauthier; Kai-Keen Shiu; Nicholas Orr; Sami Shousha; Zoran Gatalica; Alan Mackay; Jose Palacios; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2011-10-20       Impact factor: 7.996

10.  Development and characterization of xenograft model systems for adenoid cystic carcinoma.

Authors:  Christopher A Moskaluk; Alexander S Baras; Stefani A Mancuso; Hao Fan; Robert J Davidson; Dawn C Dirks; Wendy L Golden; Henry F Frierson
Journal:  Lab Invest       Date:  2011-06-27       Impact factor: 5.662

View more
  7 in total

1.  Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.

Authors:  Vatche Tchekmedyian; Eric J Sherman; Lara Dunn; Crystal Tran; Shrujal Baxi; Nora Katabi; Cristina R Antonescu; Irina Ostrovnaya; Sofia S Haque; David G Pfister; Alan L Ho
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

2.  Analysis of clinicopathological characteristics, MYB rearrangement and prognostic factors in salivary adenoid cystic carcinoma.

Authors:  Jing Han; Chunye Zhang; Ting Gu; Xi Yang; Longwei Hu; Zhen Tian; Jiang Li; Chenping Zhang
Journal:  Oncol Lett       Date:  2019-01-15       Impact factor: 2.967

3.  Adenoid cystic carcinoma of the orbit with bilateral cavernous sinus extension: A case report.

Authors:  Faris M Al Ghulaiga; Hattan Alkhiary; Hisham AlKhalidi; Hind M Alkatan
Journal:  Int J Surg Case Rep       Date:  2022-09-10

4.  Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.

Authors:  Petr Šteiner; Simon Andreasen; Petr Grossmann; Lukáš Hauer; Tomáš Vaněček; Markéta Miesbauerová; Thalita Santana; Katalin Kiss; David Slouka; Alena Skálová
Journal:  Virchows Arch       Date:  2018-04-04       Impact factor: 4.064

5.  The Utility of MYB Immunohistochemistry (IHC) in Fine Needle Aspiration (FNA) Diagnosis of Adenoid Cystic Carcinoma (AdCC).

Authors:  Tong Sun; Ali Akalin; Karen Dresser; Andrew H Fischer; Tao Zuo
Journal:  Head Neck Pathol       Date:  2020-07-13

6.  Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland.

Authors:  Jingxue Zhang; Xuejing Yan; Rui Liu; Shen Wu; Qian Liu; Jing Li; Jianmin Ma
Journal:  Cancer Manag Res       Date:  2022-03-06       Impact factor: 3.989

7.  miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L.

Authors:  Jie Hao; Xin Jin; Yan Shi; Hong Zhang
Journal:  Cancer Cell Int       Date:  2018-05-09       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.